Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient

John Yeakel; Aarthi Kannan; Nicole Hook Rattigan; Maki Yamamoto; Alexey Aleshin; Jeremy P Harris; Ling Gao

doi:10.1016/j.jdcr.2021.10.025

Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient

JAAD Case Rep. 2021 Oct 30:18:94-98. doi: 10.1016/j.jdcr.2021.10.025. eCollection 2021 Dec.

Authors

John Yeakel¹, Aarthi Kannan², Nicole Hook Rattigan³, Maki Yamamoto⁴, Alexey Aleshin³, Jeremy P Harris¹, Ling Gao^{2

5

6}

Affiliations

¹ Department of Radiation Oncology, University of California, Irvine, California.
² Department of Dermatology, University of California, Irvine, California.
³ Natera, Inc, Austin, Texas.
⁴ Department of Surgery, University of California, Irvine, California.
⁵ Veterans Affairs Long Beach Healthcare System, Long Beach, California.
⁶ Southern California Institute for Research and Education, Long Beach, California.

No abstract available

Keywords: CT, computed tomography; CtDNA, cell-free circulating tumor DNA; HRT, hypofractionated radiation; ICIs, immune checkpoint inhibitors; MCC, Merkel cell carcinoma; MTM, mean tumor molecules; Merkel cell carcinoma; T-VEC; T-VEC, talimogene laherparepvec; circulating tumor DNA; hypofractionated radiation.

Publication types

Case Reports

Grants and funding

P30 AR075047/AR/NIAMS NIH HHS/United States